Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage
- 1Human Performance Laboratory, University of Vermont, Burlington, VT, USA
- 2Nicholas Institute of Sports Medicine and Athletic Trauma, Lenox Hill Hospital, New York, NY, USA
- 3Department of Food Science & Technology, Cornell University, Geneva, NY, USA
- Correspondence to: Dr Connolly Human Performance Laboratory, University of Vermont, Burlington, VT 05405, USA;
- Accepted 16 May 2006
- Published Online First 21 June 2006
Background: Numerous antioxidant and anti-inflammatory agents have been identified in tart cherries.
Objective: To test the efficacy of a tart cherry juice blend in preventing the symptoms of exercise induced muscle damage.
Methods: This was a randomised, placebo controlled, crossover design. Fourteen male college students drank 12 fl oz of a cherry juice blend or a placebo twice a day for eight consecutive days. A bout of eccentric elbow flexion contractions (2 × 20 maximum contractions) was performed on the fourth day of supplementation. Isometric elbow flexion strength, pain, muscle tenderness, and relaxed elbow angle were recorded before and for four days after the eccentric exercise. The protocol was repeated two weeks later with subjects who took the placebo initially, now taking the cherry juice (and vice versa). The opposite arm performed the eccentric exercise for the second bout to avoid the repeated bout protective effect.
Results: Strength loss and pain were significantly less in the cherry juice trial versus placebo (time by treatment: strength p<0.0001, pain p = 0.017). Relaxed elbow angle (time by treatment p = 0.85) and muscle tenderness (time by treatment p = 0.81) were not different between trials.
Conclusions: These data show efficacy for this cherry juice in decreasing some of the symptoms of exercise induced muscle damage. Most notably, strength loss averaged over the four days after eccentric exercise was 22% with the placebo but only 4% with the cherry juice.
Published Online First 21 June 2006
Competing interests: the authors each have 2.5% equity in Cherrypharm Inc.